Overview

Phase 3 Extension Study of Dexpramipexole in ALS

Status:
Terminated
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to collect long-term safety data from subjects with Amyotrophic Lateral Sclerosis (ALS) exposed to dexpramipexole.
Phase:
Phase 3
Details
Lead Sponsor:
Knopp Biosciences
Collaborator:
Biogen
Treatments:
Pramipexole